United States Renal Data System

United States Renal Data System is a national registry whose kidney-transplantation analyses helped convert scattered clinical observations about hepatitis C into population-level evidence. In the book’s account, its data connect donor and recipient serology with survival, graft failure, post-transplant diabetes, and the difficult choice between remaining on dialysis and accepting an organ from a hepatitis C-positive donor.

Institutional Role and Evidence Base

United States Renal Data System appears within a broader evidence network concerned with hepatitis C in chronic kidney disease, dialysis, and transplantation. The field distinguishes antibody positivity from active infection: chronic infection requires both anti-HCV antibodies and detectable HCV RNA, while antibody testing alone cannot establish whether infection has resolved or remains active. That distinction matters when registry records classify patients by serology and when clinicians interpret outcomes attributed to hepatitis C. The registry’s importance lies in scale. Smaller center-based series could examine carefully selected donor-recipient pairs, but registry analyses could compare much larger populations across ordinary clinical practice. The book nevertheless emphasizes that registry findings are observational and may reflect differences in baseline risk, donor and recipient characteristics, allocation policy, and the completeness of viral-status information rather than a simple causal effect of donor seropositivity.

Findings on Hepatitis C and Survival

Registry evidence formed part of the larger record showing that hepatitis C is associated with excess mortality in patients receiving long-term dialysis. Across dialysis cohorts, anti-HCV positivity was independently associated with reduced survival; the book cites a United States Renal Data System analysis describing an increased mortality risk and places it alongside findings from the Dialysis Outcomes and Practice Patterns Study, Japan, and Australia and New Zealand. Other studies reported that liver-related death was much more frequent among anti-HCV-positive dialysis patients, even though many patients died before the long-term complications of cirrhosis or hepatocellular carcinoma could develop. The same survival question continued after kidney transplantation. HCV-infected kidney transplant recipients generally had worse long-term survival than recipients without evidence of infection, with the adverse difference becoming most apparent in studies extending beyond ten years after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79 for recipients with hepatitis C, with part of the excess attributed to liver-related death. These findings did not mean that dialysis was safer: among HCV-infected patients with end-stage renal disease, transplantation still provided a survival advantage over remaining on the waiting list when advanced liver injury was absent.

Donor Seropositivity and Conflicting Results

United States Renal Data System analyses examined kidneys from hepatitis C-positive donors in relation to recipient hepatitis C status. One registry-based body of work reported decreased patient survival after transplantation from hepatitis C-positive donors compared with hepatitis C-negative donors, regardless of the recipient’s serologic status, with the difference becoming apparent approximately two years after transplantation. The investigators proposed that post-transplant diabetes mellitus might be an intermediate complication contributing to the later increase in mortality and urged caution, careful evaluation, and complete disclosure to potential recipients. The registry comparisons were difficult to interpret because recipients of kidneys from hepatitis C-positive donors often began with a worse clinical and immunological profile. They were more likely to be older, to have advanced donor or recipient age, to be African-American, and to have a high rate of dialysis-access complications. The organs were also sometimes used in recipients who were HCV-negative, and registry records did not consistently identify whether recipients had detectable HCV RNA at transplantation. These imbalances could make donor seropositivity appear more harmful than it was in a deliberately matched or policy-controlled cohort. At the same time, United States Renal Data System work identified a substantial advantage for HCV-positive recipients who accepted kidneys from HCV-positive donors. Such recipients waited 310 fewer days than the average waiting time at their center and 395 fewer days than comparable recipients who waited for HCV-negative kidneys. Most importantly, transplantation with an HCV-positive kidney was independently associated with better survival than remaining on the waiting list, with an adjusted hazard ratio of 0.76. The registry therefore presented the donor-positive organ not only as a possible source of post-transplant risk, but also as a way to shorten exposure to the considerable mortality risk of prolonged dialysis.

Graft Survival and Interpretation

Registry evidence also suggested poorer graft survival among anti-HCV-positive recipients. In the Australian and New Zealand Dialysis and Transplant Registry, five-year graft survival was worse in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss in that group was more often attributed to glomerulonephritis and chronic allograft nephropathy. Earlier comparative work likewise reported an adjusted relative risk of graft loss of 1.53 among 488 anti-HCV-positive recipients compared with 2,877 seronegative recipients, although other prospective and retrospective studies found nonsignificant reductions in graft loss. The contrast between United States Renal Data System results and center-based Spanish experience is central to the book’s evaluation of the evidence. In a long-term Spanish comparison of 162 HCV-positive recipients of kidneys from HCV-positive donors and 306 HCV-positive recipients of kidneys from HCV-negative donors, patient survival did not differ, and deaths from liver disease were uncommon in both groups. Donor HCV-positive serology was not an independent risk factor for death, graft loss, advanced liver disease, or post-transplant glomerular disease. The registry’s less favorable findings may therefore reflect selection and allocation differences, including older donors and recipients and a greater prevalence of pretransplant viremia, rather than an inevitable consequence of receiving an HCV-positive kidney.

Significance for Transplant Policy

United States Renal Data System made the transplantation decision visible as a time-dependent balance rather than a binary judgment about whether hepatitis C-positive organs were safe. The book’s broader evidence shows that transplantation can sharply reduce mortality among HCV-infected patients compared with remaining on dialysis, while hepatitis C itself can increase the risks of liver disease, infection-related death, graft failure, and chronic allograft nephropathy. Within that balance, a positive donor kidney may shorten waiting time and improve survival for an HCV-positive candidate, but its use requires attention to recipient viral status, liver injury, donor and recipient risk, post-transplant diabetes, and long-term graft outcomes. The registry’s lasting contribution is thus methodological as well as clinical. It expanded the evidence beyond individual centers, exposed outcomes that emerged only after years of follow-up, and demonstrated how allocation practices shape apparent treatment effects. Its findings did not settle the question through randomized comparison; instead, they helped clinicians weigh the immediate survival benefit of transplantation against uncertain long-term complications and supported a policy of informed, carefully selected use rather than either unrestricted acceptance or blanket exclusion of hepatitis C-positive kidneys.